Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma
For uHCC patients, combination therapy can provide better OS and PFS compared to HAIC alone.
Authors
- Lujun Shen (ORCID: https://orcid.org/0000-0002-7936-0206)
- Wen Liu (ORCID: https://orcid.org/0000-0003-2757-6504)
- Bofu Liu
- X. Wang (ORCID: https://orcid.org/0009-0004-8457-6580)
- Jieqiong Lei (ORCID: https://orcid.org/0000-0002-6187-8576)
- Weijun Fan (ORCID: https://orcid.org/0000-0002-8757-647X)
- Qinquan Tan (ORCID: https://orcid.org/0000-0002-6245-4652)
- Zhengguo Li (ORCID: https://orcid.org/0000-0002-6029-2178)
- Zhiyong Zhang (ORCID: https://orcid.org/0000-0001-9130-9916)
- Hengfei Huang
Institutions
- Sun Yat-sen University (CN)
- Gansu Provincial Hospital (CN)
- Dongguan People’s Hospital (CN)
- Lanzhou University Second Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Chongqing Dazu District People's Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/jhc.s470345
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.48